PDSB - PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy
2023-11-09 10:40:49 ET
More on PDS Biotechnology
- PDS Biotechnology: PDS0101 Being Put To The Test
- PDS Biotechnology (PDSB) Q2 2023 Earnings Call Transcript
- PDS Biotechnology: Interim Data Reinforces Push Towards Phase 3 Study
- PDS Biotech posts Phase 1/2 data for prostate cancer therapy
- PDS Biotech updates Phase 2 data for lead asset in head and neck cancer
For further details see:
PDS Biotech reports encouraging survival data for HPV 16+ cancer therapy